Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Clin Cancer Res. 2021 Mar 16;27(11):3017–3027. doi: 10.1158/1078-0432.CCR-21-0024

Table 5.

Molecular Alterations in Study Cohort.

N %
ETS Fusion 22 55.0%
PTEN 17 42.5%
TP53 11 27.5%
WNT 9 22.5%
KMT2C 8 20.0%
SPOP 6 15.0%
PIK3 pathway 5 12.5%
CHD1 5 12.5%
FoxA1 4 10.0%
BRCA1/2 3 7.5%
AR 2 5.0%
CDK12 2 5.0%
ZFHX3 2 5.0%
KRAS 2 5.0%
CCND1 1 2.5%
ATM 1 2.5%
8p loss 35 87.5%
8q gain 18 45.0%
13q loss 18 45.0%
7p gain 6 15.0%